OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

• Status: Not yet recruiting
• Trial end date: 2033-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®).

In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gangnam Severance Hospital
• Collaborator: Seoul National University

Criteria

Inclusion Criteria:

• ER+HER2- breast cancer

• Premenopausal and age <=50

• T1-3/N1

• N1 including micrometastasis

• Genomic Low Risk by OncoFREE test® (1-20)

Exclusion Criteria:

• Postmenopausal women

• ER-negative breast cancer